Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00471185 · ClinicalTrials.gov registry record · Phase 1
ACY-6 Oral Administration of Acyline
A Phase 1 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT00471185 is a Phase 1 study that has completed, run by University of Washington. The registered enrollment target is 9 participants.
The verdict
NCT00471185, a Phase 1 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
In this study, we propose oral dosing of GIPET enhanced oral acyline (MER-104) to determine if this potentially useful compound is safe and effective at suppression of gonadotropins after oral dosing in man. Hypothesis: A single dose of Acyline will suppress gonadotropins, and testosterone, estradiol and dihydrotestosterone (DHT) for 24 hours in man, and the magnitude and duration of the suppression will increase with increasing doses of Acyline.
Interventions
- DRUG Acyline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2007-06 |
| Est. Completion | 2007-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00471185
The ClinicalTrials.gov registry entry for NCT00471185 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Acyline is the first listed.
NCT00471185 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00471185 about?
NCT00471185 is a clinical study titled "ACY-6 Oral Administration of Acyline". In this study, we propose oral dosing of GIPET enhanced oral acyline (MER-104) to determine if this potentially useful compound is safe and effective at suppression of gonadotropins after oral dosing in man. Hypothesis: A single dose of Acyline will suppress gonadotropins, and testosterone, estradi...
What is the current status of trial NCT00471185?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2007-06. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00471185?
The interventions under investigation include: Acyline (DRUG).
Who is sponsoring clinical trial NCT00471185?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.